Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. reports developments in regenerative and cellular medicine, including longevity-focused programs, placental-derived cell therapies and commercial regenerative medicine products such as Biovance and Biovance 3L. Company news also covers clinical and coverage-related updates, operating and financial results, capital-structure actions and governance matters.
Recurring corporate updates include periodic-reporting status, Nasdaq compliance, tax-credit monetization, material agreements and shareholder matters. The company's disclosures also reference its common stock and warrants trading on Nasdaq under CELU and CELUW.
Celularity (Nasdaq: CELU) and Fountain Life announced that cenplacel-L, a placental-derived allogeneic investigational cell therapy, will be available for physician-directed investigational use in Florida under new regenerative medicine statutes effective July 1, 2025.
The partnership leverages Celularity’s FDA-registered, GMP-compliant facility and Fountain Life’s preventive, longevity-focused care model.
Celularity (Nasdaq: CELU) released a CEO letter outlining a sharper focus on placental-derived cellular therapies for longevity and age-related disease.
The company out-licensed its biomaterials business to NexGel for up to $30 million, eliminated nearly $13 million of recorded liabilities, highlighted growing physician demand for cenplacel-L, emphasized early commercial efforts in Florida with Fountain Life, and announced Rick Gonzalez as Chief Commercial Officer while acknowledging residual debt and capital constraints.
Celularity (Nasdaq: CELU) appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. He will lead global commercialization of cenplacel-L, the Lifebank cellular banking platform and the broader regenerative medicine portfolio, reporting to CEO Robert J. Hariri.
Gonzalez brings 20+ years of biotech and medtech leadership, including roles at Alume Biosciences, Navidea Biopharmaceuticals and Spectrum Pharmaceuticals, where he previously helped drive significant revenue expansion. Celularity cites growing physician demand in permissive markets for cenplacel-L and ongoing 2025 Lifebank sales as drivers to strengthen commercial capabilities.
Celularity (Nasdaq: CELU) received a Nasdaq notice on May 27, 2026 for not timely filing its Form 10-Q for the quarter ended March 31, 2026, breaching Nasdaq Listing Rule 5250(c)(1). The notice does not immediately affect CELU’s Nasdaq Capital Market listing or trading.
Celularity has until July 28, 2026 to submit a compliance plan, and Nasdaq may grant up to 180 days from the Form 10-Q due date, to November 16, 2026. The company is working to file the report and expects to regain full reporting compliance.
Celularity (Nasdaq: CELU) filed its Annual Report on Form 10-K for fiscal 2025 on May 1, 2026 and has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company said it completed strategic actions including an out-license of its biomaterials portfolio, a realignment of non-core personnel and a $13 million reduction in recorded liabilities. Management characterized the moves as sharpening strategic focus and strengthening the balance sheet to concentrate on core longevity and cell therapy platforms.
Celularity (Nasdaq: CELU) closed a transaction with NexGel on April 21, 2026, selling certain commercial and other assets from its biomaterials product portfolio.
Celularity received $13.3 million consideration: $8.3M cash at closing and a $5.0M convertible promissory note, plus up to $20.0M in milestone payments and royalties. The deal enabled retirement of nearly $13.0M of debt and aims to refocus resources on Celularity’s longevity therapeutic pipeline and manufacturing platform.
Celularity (Nasdaq: CELU) received a Nasdaq notice on April 16, 2026 for late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The notice says the company is not currently compliant with Nasdaq Listing Rule 5250(c)(1), but trading of CELU and CELUW continues. Celularity has 60 days to submit a compliance plan and may receive up to 180 days if Nasdaq accepts the plan. The company is working to file the Form 10-K and currently expects to do so in the coming weeks, but offers no assurance it will regain compliance.
Celularity (Nasdaq: CELU) reiterated its strategic commercialization partnership with NEXGEL (Nasdaq: NXGL) to license established biomaterial products and three 510(k) pathway programs. Celularity will be the exclusive manufacturer at its FDA-compliant Florham Park, New Jersey facility.
The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions, and aims to leverage renewed regulatory and reimbursement clarity for placental-derived biomaterials.
Celularity (NASDAQ: CELU) entered definitive agreements to grant an exclusive license for its commercial-stage placental-derived biomaterials and certain development-stage programs, with upfront and milestone payments totaling up to $35 million and potential future royalties.
Celularity will remain the exclusive manufacturer at its Florham Park FDA-compliant facility, creating ongoing manufacturing revenue, and will realign operations to focus on longevity-focused cellular therapeutics and capital efficiency.
Celularity (Nasdaq: CELU) received $12.2 million in net cash proceeds from selling approximately $126.3 million of New Jersey net operating losses and $1.9 million of unused New Jersey R&D tax credits on Feb 10, 2026.
The sale was completed through New Jersey’s Technology Business Tax Certificate Transfer Program administered by the NJEDA, providing non-dilutive, tax-free capital to strengthen liquidity and support commercial and GMP-level cell therapy programs.